Nightingale Health Ltd. is a pioneering Finnish biotech company, transforming healthcare and research through use of its innovative blood analysis service. By providing comprehensive and cost-effective data on blood, Nightingale’s mission is to solve the world’s number one health problem - chronic diseases. At the heart of its technology is a combination of NMR-based analysis and proprietary software that generates data used by researchers and clinicians to improve risk prediction of diseases, such as diabetes and cardiovascular diseases. There are currently over 100 scientific publications that have successfully applied Nightingale’s method, including major metabolomics and epidemiological studies. Nightingale is built on an unrivalled scientific foundation, comprising of an interdisciplinary team of experts in computational medicine, healthcare IT and business. With headquarters and laboratory facilities in Finland (along with two franchising laboratories in the UK), Nightingale routinely provide services for academic research and industrial R&D customers internationally. The next major milestone for the company will be bringing its blood analysis platform to global healthcare providers. Nightingale is a member of one the world's biggest health-focused start-up accelerators StartUp Health. Chosen as an Official Solver by MIT's Solver program.